Biologic drugs are pushing the boundaries of medicine, and their potential to benefit patients with unmet medical needs has never been more promising. For example, researchers are using a viral therapy to treat advanced melanoma by targeting only cancerous cells, and prompting the patient’s immune system to attack them as well.
Christine Simmon, AAM Senior Vice President of Policy and Strategic Alliances and Executive Director of the Biosimilars Council, invites industry professionals to attend GRx+Biosims 2018 on Sept. 5-7 in Baltimore, MD. This year, we are combining FallTech, Leading on Biosimilars, and CMC Workshop to one can't-miss opportunity to connect with peers around the world. Attend GRx+Biosims to hear the latest from top-in-their-field speakers and government officials, share best practices and discover new learning tracks in the generic and biosimilars industry.
Christine Simmon, Executive Director of AAM's Biosimilars Council, reacts to the recent release of FDA's Biosimilars Action Plan
Agency’s Commitment to Competition, Efficient Development and Approval Process Lauded
Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion with Molly Burich (Boehringer Ingelheim), Mark Fleury (American Cancer Society’s Cancer Action Network), Greg Gierer (America’s Health Insurance Plans) and Patrick Vallano (Mylan).
Biosimilars hold the key to ensuring affordable access to biologic medicines for all consumers. The Biosimilars Council exists to educate, advocate, and promote the development of these products through resources such as this handbook.
This handbook is designed to be a reference tool for health care professionals as well as patients interested in learning more about biosimilars and interchangeable biologics.
Biosimilars have the potential to improve quality of life for patients. If the right policies are put in place to cultivate a robust market, an additional 1.2 million patients will have access to biologic medicines, while also saving an estimated $54 billion over the next 10 years.